ArticleAntiviral research2016
Single dose of an adenovirus vectored mouse interferon-α protects mice from lethal EV71 challenge.
Article in Antiviral research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Experimental animal models for development of human enterovirus vaccine.Clinical and experimental vaccine research · 2023Review
- Research progress on pathogenic and therapeutic mechanisms of Enterovirus A71.Archives of virology · 2023Review
- AAV-CRISPR-Cas13 eliminates human enterovirus and prevents death of infected mice.EBioMedicine · 2023Article
- TBK1 and IRF3 are potential therapeutic targets in Enterovirus A71-associated diseases.PLoS neglected tropical diseases · 2023Article
- Pharmacological perturbation of CXCL1 signaling alleviates neuropathogenesis in a model of HEVA71 infection.Nature communications · 2022Article
- Novel capsid binder and PI4KIIIbeta inhibitors for EV-A71 replication inhibition.Scientific reports · 2021Article
- Adenovirus vectored IFN-α protects mice from lethal challenge of Chikungunya virus infection.PLoS neglected tropical diseases · 2020Article
- Drug repurposing of pyrimidine analogs as potent antiviral compounds against human enterovirus A71 infection with potential clinical applications.Scientific reports · 2020Article
- Molecular Pathogenicity of Enteroviruses Causing Neurological Disease.Frontiers in microbiology · 2020Review
- Hypoxia and therapeutic treatment of EV-A71 with an immune modulator TLR7 agonist in a new immunocompetent mouse model.Journal of biomedical science · 2019Article
- Global virus outbreaks: Interferons as 1st responders.Seminars in immunology · 2019Review
- Immunocompetent and Immunodeficient Mouse Models for Enterovirus 71 Pathogenesis and Therapy.Viruses · 2018Review
- Innate Immunity Evasion by Enteroviruses Linked to Epidemic Hand-Foot-Mouth Disease.Frontiers in microbiology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enterovirus 71 (EV71) causes hand-foot-and-mouth diseases as well as neurological complications in young children. Interferon (IFN) can inhibit the replication of many viruses with low cytotoxic effects. Previously, an adenovirus vectored mouse interferon-α (DEF201), subtype 5, was generated by Wu et al, 2007. In this study, the antiviral effects of DEF201 against EV71 were evaluated in a murine model. 6-day-old BALB/c mice were administered a single dose of DEF201 before or after infection with lethal dose of EV71. The survival rate, clinical symptoms, tissue viral loads and histology pathogenesis were evaluated. IFN gene expression following a single dose of DEF201 maintained high concentrations of 100-9000 pg/mL for more than 7 days in mice serum. Pre-infection administration of a single dose of 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.